|Aravasc is developing a loco-regional multi-functional theranostic
delivery system (MTDS). The MTDS is designed to deliver
combination chemotherapeutics over several weeks, to the cancer site
to avoid crippling systemic toxicities. It is also engineered to deliver a
fluorescent dye that lights up the tumor vasculature enabling
monitoring of the cancer therapy. The initial focus of the platform
technology is in gastro-intestinal cancers.